Pulmonary hypertension screening in systemic sclerosis: Apropos 67 patients;Dépistage de l'hypertension artérielle pulmonaire au cours de la sclérodermie systémique: Étude d'une cohorte de 67 patients

Revue de Medecine Interne

Volumn 22, Issue 9, 2001, Pages 819-829

  Launay, D ^a   Hachulla, E ^a   Hatron, P Y ^a   Michon Pasturel, U ^a   Hebbar, M ^a   Queyrel, V ^a   Goullard, L ^a   Robin, S ^a   Remy Jardin M ^a   Devulder, B ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

CREST syndrome; Lung; Pulmonary hypertension; Spirometry; Systemic sclerosis

Indexed keywords

CARDIOLIPIN ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; EARLY DIAGNOSIS; FEMALE; HUMAN; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PULMONARY HYPERTENSION; SPIROMETRY; SYNDROME CREST; SYSTEMIC SCLEROSIS;

EID: 17744405338     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(01)00433-7     Document Type: Article

References (38)

1. Atteinte pulmonaire au cours de la sclérodermie systémique. Partie II. Hypertension artérielle pulmonaire isolée, cancer bronchopulmonaire, hémorragie alvéolaire
2. Prevalence of pulmonary hypertension in limited and diffuse scleroderma
3. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients
4. Predictors of survival in systemic sclerosis (scleroderma)
5. L'hypertension artérielle pulmonaire primitive: Une complication rare mais souvent mortelle du Crest syndrome
6. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis
7. Recognition and management of pulmonary hypertension
8. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
9. Aerosolized ilomedine in severe pulmonary hypertension in systemic sclerosis
10. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis
11. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
12. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
13. The second international anticardiolipin standardization workshop/The kingstone antiphospholipid antibody study group
14. Pulmonary involvement in progressive systemic sclerosis: Sequential evaluation with CT, pulmonary function tests and bronchoalveolar lavage
15. Standardization of the measurements of transfer factor (diffusing capacity). Report working party standardization of lung function tests, European Community for Steel and Coal. Official statement of the European Society
16. Continuous-wave Doppler determination of right ventricular pressure: A simultaneous Doppler-catheterization study in 127 patients
17. Noninvasive assessment of pressure drop in mitral stenosis by Doppler ultrasound
18. Polymyositis and dermatomyositis first of two parts
19. The pulmonary pathologic manifestations of the CREST syndrome
20. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis
21. Lung disease in systemic sclerosis (scleroderma)
22. Non invasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation
23. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis
24. Doppler estimation of pulmonary artery pressures revisited
25. Pulmonary hypertension in systemic sclerosis
26. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma)
27. Pathologic observations in systemic sclerosis
28. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents
29. Pulmonary involvement in systemic sclerosis (scleroderma)
30. Organ involvement : Pulmonary
31. Scleroderma. Clinical problems. The lungs
32. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension
33. Relationship between antiphospholipid and anti-endothelial cell antibodies: Further characterization of the reactivity on resting and cytokine-activated endothelial cells
34. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro or in vivo
35. Cardiopulmonary manifestations of systemic sclerosis
36. Isolated diffusing capacity reduction in systemic sclerosis
37. Atteinte pulmonaire au cours de la sclérodermie systémique. Partie I. Pneumopathie interstitielle chronique fibrosante